Evaluation of the Solid Dispersion System Engineered from Mesoporous Silica and Polymers for the Poorly Water Soluble Drug Indomethacin: In Vitro and In Vivo
This work explored absorption efficacy via an in vivo imaging system and parallel artificial membrane penetration in indomethacin (IMC) solid dispersion (SD) systems. Two different polymer excipients—hydroxypropyl methylcellulose (HPMC) and Kollicoat IR as precipitation inhibitors (PIs)—combined wit...
Saved in:
| Published in | Pharmaceutics Vol. 12; no. 2; p. 144 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI
10.02.2020
MDPI AG |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | This work explored absorption efficacy via an in vivo imaging system and parallel artificial membrane penetration in indomethacin (IMC) solid dispersion (SD) systems. Two different polymer excipients—hydroxypropyl methylcellulose (HPMC) and Kollicoat IR as precipitation inhibitors (PIs)—combined with mesoporous silica nanoparticles (MSNs) as carriers were investigated. The IMC–SDs were prepared using the solvent evaporation method and characterized by solubility analysis, infrared (IR) spectroscopy, powder X-ray diffraction (PXRD), field emission scanning electron microscopy (FESEM), and differential scanning calorimetry (DSC). It was confirmed that IMC successfully changed into an amorphous state after loading into the designed carriers. The in vitro release and stability experiments were conducted to examine the in vitro dissolution rates of IMC–SDs combined with HPMC and Kollicoat IR as PIs which both improved approximately three-fold to that of the pure drug. Finally, in vivo studies and in vitro parallel artificial membrane penetration (PAMPA) experiments ensured the greater ability of enhancing the dissolution rates of pure IMC in the gastrointestinal tract by oral delivery. In brief, this study highlights the prominent role of HPMC and Kollicoat IR as PIs in MSN SD systems in improving the bioavailability and gastrointestinal oral absorption efficiency of indomethacin. |
|---|---|
| AbstractList | This work explored absorption efficacy via an in vivo imaging system and parallel artificial membrane penetration in indomethacin (IMC) solid dispersion (SD) systems. Two different polymer excipients-hydroxypropyl methylcellulose (HPMC) and Kollicoat IR as precipitation inhibitors (PIs)-combined with mesoporous silica nanoparticles (MSNs) as carriers were investigated. The IMC-SDs were prepared using the solvent evaporation method and characterized by solubility analysis, infrared (IR) spectroscopy, powder X-ray diffraction (PXRD), field emission scanning electron microscopy (FESEM), and differential scanning calorimetry (DSC). It was confirmed that IMC successfully changed into an amorphous state after loading into the designed carriers. The in vitro release and stability experiments were conducted to examine the in vitro dissolution rates of IMC-SDs combined with HPMC and Kollicoat IR as PIs which both improved approximately three-fold to that of the pure drug. Finally, in vivo studies and in vitro parallel artificial membrane penetration (PAMPA) experiments ensured the greater ability of enhancing the dissolution rates of pure IMC in the gastrointestinal tract by oral delivery. In brief, this study highlights the prominent role of HPMC and Kollicoat IR as PIs in MSN SD systems in improving the bioavailability and gastrointestinal oral absorption efficiency of indomethacin.This work explored absorption efficacy via an in vivo imaging system and parallel artificial membrane penetration in indomethacin (IMC) solid dispersion (SD) systems. Two different polymer excipients-hydroxypropyl methylcellulose (HPMC) and Kollicoat IR as precipitation inhibitors (PIs)-combined with mesoporous silica nanoparticles (MSNs) as carriers were investigated. The IMC-SDs were prepared using the solvent evaporation method and characterized by solubility analysis, infrared (IR) spectroscopy, powder X-ray diffraction (PXRD), field emission scanning electron microscopy (FESEM), and differential scanning calorimetry (DSC). It was confirmed that IMC successfully changed into an amorphous state after loading into the designed carriers. The in vitro release and stability experiments were conducted to examine the in vitro dissolution rates of IMC-SDs combined with HPMC and Kollicoat IR as PIs which both improved approximately three-fold to that of the pure drug. Finally, in vivo studies and in vitro parallel artificial membrane penetration (PAMPA) experiments ensured the greater ability of enhancing the dissolution rates of pure IMC in the gastrointestinal tract by oral delivery. In brief, this study highlights the prominent role of HPMC and Kollicoat IR as PIs in MSN SD systems in improving the bioavailability and gastrointestinal oral absorption efficiency of indomethacin. This work explored absorption efficacy via an in vivo imaging system and parallel artificial membrane penetration in indomethacin (IMC) solid dispersion (SD) systems. Two different polymer excipients—hydroxypropyl methylcellulose (HPMC) and Kollicoat IR as precipitation inhibitors (PIs)—combined with mesoporous silica nanoparticles (MSNs) as carriers were investigated. The IMC–SDs were prepared using the solvent evaporation method and characterized by solubility analysis, infrared (IR) spectroscopy, powder X-ray diffraction (PXRD), field emission scanning electron microscopy (FESEM), and differential scanning calorimetry (DSC). It was confirmed that IMC successfully changed into an amorphous state after loading into the designed carriers. The in vitro release and stability experiments were conducted to examine the in vitro dissolution rates of IMC–SDs combined with HPMC and Kollicoat IR as PIs which both improved approximately three-fold to that of the pure drug. Finally, in vivo studies and in vitro parallel artificial membrane penetration (PAMPA) experiments ensured the greater ability of enhancing the dissolution rates of pure IMC in the gastrointestinal tract by oral delivery. In brief, this study highlights the prominent role of HPMC and Kollicoat IR as PIs in MSN SD systems in improving the bioavailability and gastrointestinal oral absorption efficiency of indomethacin. This work explored absorption efficacy via an in vivo imaging system and parallel artificial membrane penetration in indomethacin (IMC) solid dispersion (SD) systems. Two different polymer excipients-hydroxypropyl methylcellulose (HPMC) and Kollicoat IR as precipitation inhibitors (PIs)-combined with mesoporous silica nanoparticles (MSNs) as carriers were investigated. The IMC−SDs were prepared using the solvent evaporation method and characterized by solubility analysis, infrared (IR) spectroscopy, powder X-ray diffraction (PXRD), field emission scanning electron microscopy (FESEM), and differential scanning calorimetry (DSC). It was confirmed that IMC successfully changed into an amorphous state after loading into the designed carriers. The in vitro release and stability experiments were conducted to examine the in vitro dissolution rates of IMC−SDs combined with HPMC and Kollicoat IR as PIs which both improved approximately three-fold to that of the pure drug. Finally, in vivo studies and in vitro parallel artificial membrane penetration (PAMPA) experiments ensured the greater ability of enhancing the dissolution rates of pure IMC in the gastrointestinal tract by oral delivery. In brief, this study highlights the prominent role of HPMC and Kollicoat IR as PIs in MSN SD systems in improving the bioavailability and gastrointestinal oral absorption efficiency of indomethacin. |
| Author | Xi, Ziyue Xu, Lu Zhang, Wei Cui, Mingshu Chen, Lu Xie, Luyao Fei, Yali |
| AuthorAffiliation | School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China; lnxiziyue@163.com (Z.X.); zhangwei9501@126.com (W.Z.); f18309806223@126.com (Y.F.); cui_mingshu@126.com (M.C.); xieluyao0221@163.com (L.X.); chenlu182125@163.com (L.C.) |
| AuthorAffiliation_xml | – name: School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China; lnxiziyue@163.com (Z.X.); zhangwei9501@126.com (W.Z.); f18309806223@126.com (Y.F.); cui_mingshu@126.com (M.C.); xieluyao0221@163.com (L.X.); chenlu182125@163.com (L.C.) |
| Author_xml | – sequence: 1 givenname: Ziyue surname: Xi fullname: Xi, Ziyue – sequence: 2 givenname: Wei surname: Zhang fullname: Zhang, Wei – sequence: 3 givenname: Yali surname: Fei fullname: Fei, Yali – sequence: 4 givenname: Mingshu surname: Cui fullname: Cui, Mingshu – sequence: 5 givenname: Luyao surname: Xie fullname: Xie, Luyao – sequence: 6 givenname: Lu surname: Chen fullname: Chen, Lu – sequence: 7 givenname: Lu orcidid: 0000-0002-8739-692X surname: Xu fullname: Xu, Lu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32050600$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kt1uFCEUxyemxtbaR9Bw6c0qDDMwaGJi2lU3qbHJ-nFJGDizS8PACkyTfRjfVXa3Na0xcgPn6_eHc3haHfngoaqeE_yKUoFfb9YqjkrDlK1OpMY1Jk3zqDohQohZI2p6dO98XJ2ldI3LopR0VDypjmmNW8wwPql-zW-Um1S2waMwoLwGtAzOGnRh0wZi2vmX25RhRHO_sh4ggkFDDCP6DClsQgxTQkvrrFZIeYOugtuOpRANIe5xVyFEt0U_VIa4Y0-9A3QRpxVaeBNGyGulrX9TLPTd5hj2lL1xE55VjwflEpzd7qfVtw_zr-efZpdfPi7O31_OdMN5nvFG923HesYIN4LhWmgFmtQd1VSxgZvyWKZ7wowGwwXGnFGuhRlAd63qMD2tFgeuCepabqIdVdzKoKzcO0JcSRVLrx1IrFvFWlY3nJEGD13Phs7Q1nBCS2RQhfXuwNpM_QhF0eeo3APow4i3a7kKN5LvrtW1BfDyFhDDzwlSlqNNGpxTHkqzZU3bhlNRs7qkvriv9Ufkbr4l4e0hQceQUoRBapv30y7S1kmC5e5DyX9-qFLd_lV9J_D_ut8j9db7 |
| CitedBy_id | crossref_primary_10_3390_polym16152174 crossref_primary_10_3390_pharmaceutics14122703 crossref_primary_10_1016_j_ejpb_2021_04_017 crossref_primary_10_1208_s12249_022_02311_y crossref_primary_10_1039_D4CE00811A crossref_primary_10_1039_D4PM00113C crossref_primary_10_1089_adt_2020_992 crossref_primary_10_3390_pharmaceutics13101682 crossref_primary_10_1016_j_onano_2022_100073 crossref_primary_10_1016_j_ijpharm_2024_124179 crossref_primary_10_1016_j_ejpb_2021_03_016 crossref_primary_10_3390_molecules28083406 crossref_primary_10_1007_s11094_023_02880_7 crossref_primary_10_3390_molecules29030715 crossref_primary_10_1016_j_molstruc_2022_134373 crossref_primary_10_1021_acs_molpharmaceut_0c00811 |
| Cites_doi | 10.1016/j.ejpb.2012.02.004 10.1016/j.ijpharm.2017.10.041 10.3390/biom9070281 10.3109/03639049209043713 10.3390/pharmaceutics11070328 10.3109/03639045.2015.1024683 10.1016/j.ijpharm.2019.06.006 10.1023/A:1007516718048 10.1002/jps.20906 10.1016/j.ejpb.2019.03.002 10.1021/mp500573z 10.1016/j.jconrel.2018.04.014 10.1016/j.ejpb.2017.10.001 10.1016/j.ejpb.2018.10.007 10.1038/mi.2017.106 10.1021/acs.molpharmaceut.8b00488 10.1016/j.ijpharm.2018.11.015 10.1088/1748-6041/10/6/065012 10.1021/acsami.6b05370 10.1016/j.ijpharm.2018.04.053 10.1021/acs.langmuir.5b00246 10.3389/fbioe.2019.00225 10.1208/s12249-019-1373-4 10.1038/s41588-018-0318-2 10.1016/j.ejps.2016.11.001 10.1016/j.ejpb.2010.04.009 10.1016/j.ejps.2018.12.010 10.1007/s11095-014-1385-4 10.1208/s12249-011-9720-0 10.1021/acs.molpharmaceut.7b00930 10.1016/j.ijpharm.2016.08.034 10.1016/j.ijpharm.2019.03.014 10.1080/10717544.2017.1422298 10.1002/jps.24023 10.1039/C8NR00872H 10.1021/mp400299a 10.1080/03639045.2016.1205598 10.1016/j.bbrc.2017.10.058 10.1016/j.ejpb.2019.03.020 10.1016/j.jconrel.2009.01.027 10.1016/j.ejpb.2015.04.031 10.3390/pharmaceutics11060269 10.1007/s11095-019-2632-5 |
| ContentType | Journal Article |
| Copyright | 2020 by the authors. 2020 |
| Copyright_xml | – notice: 2020 by the authors. 2020 |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3390/pharmaceutics12020144 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1999-4923 |
| ExternalDocumentID | oai_doaj_org_article_0c5a6562476140f8b6f8d35d713c5afa PMC7076385 32050600 10_3390_pharmaceutics12020144 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Career Development Support Plan for Young and Middle-aged Teachers in Shenyang Pharmaceutical University grantid: ZQN2018005 |
| GroupedDBID | --- 53G 5VS 8G5 AADQD AAYXX ABDBF ABUWG ACGFO ACIHN ACUHS AEAQA AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AZQEC BENPR BPHCQ CCPQU CITATION DIK DWQXO EBD ESX F5P FD6 GNUQQ GROUPED_DOAJ GUQSH GX1 HH5 HYE IHR KQ8 M2O M48 MK0 MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RNS RPM TR2 TUS 3V. NPM 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c477t-74cb586b6617d96029caec1283c3a6f7d5066cb16dced79007637c9dfec85a803 |
| IEDL.DBID | M48 |
| ISSN | 1999-4923 |
| IngestDate | Wed Aug 27 01:28:08 EDT 2025 Thu Aug 21 17:55:15 EDT 2025 Fri Jul 11 01:12:37 EDT 2025 Thu Jan 02 22:58:11 EST 2025 Tue Jul 01 03:35:45 EDT 2025 Thu Apr 24 22:56:48 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | mesoporous silica nanoparticles solubility bioavailability solid dispersion indomethacin |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c477t-74cb586b6617d96029caec1283c3a6f7d5066cb16dced79007637c9dfec85a803 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-8739-692X |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/pharmaceutics12020144 |
| PMID | 32050600 |
| PQID | 2354739262 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_0c5a6562476140f8b6f8d35d713c5afa pubmedcentral_primary_oai_pubmedcentral_nih_gov_7076385 proquest_miscellaneous_2354739262 pubmed_primary_32050600 crossref_citationtrail_10_3390_pharmaceutics12020144 crossref_primary_10_3390_pharmaceutics12020144 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20200210 |
| PublicationDateYYYYMMDD | 2020-02-10 |
| PublicationDate_xml | – month: 2 year: 2020 text: 20200210 day: 10 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Pharmaceutics |
| PublicationTitleAlternate | Pharmaceutics |
| PublicationYear | 2020 |
| Publisher | MDPI MDPI AG |
| Publisher_xml | – name: MDPI – name: MDPI AG |
| References | Madgulkar (ref_29) 2016; 42 Dening (ref_9) 2018; 15 Alleso (ref_26) 2009; 136 Bhandari (ref_2) 2019; 51 ref_10 Laine (ref_4) 2016; 512 Chen (ref_39) 2019; 36 Mols (ref_5) 2010; 75 Lavra (ref_34) 2016; 43 Archer (ref_37) 1992; 18 Djuris (ref_18) 2019; 554 Alshafiee (ref_1) 2019; 137 Guzman (ref_3) 2007; 96 Peruzynska (ref_17) 2015; 10 Ma (ref_41) 2019; 561 Bertoni (ref_8) 2019; 139 Matziouridou (ref_43) 2018; 11 Raina (ref_33) 2015; 2015 Wlodarskia (ref_36) 2015; 94 Wang (ref_12) 2018; 10 Li (ref_42) 2019; 129 Chaudhary (ref_16) 2019; 7 Ueda (ref_40) 2014; 103 Zhang (ref_19) 2018; 25 ref_24 Lobmann (ref_14) 2012; 81 ref_22 Shekhawat (ref_21) 2019; 567 Wang (ref_11) 2016; 8 Schonenberger (ref_6) 2018; 133 Taylor (ref_15) 2015; 12 Kalaitzaki (ref_32) 2015; 31 Mokhtarpour (ref_35) 2019; 20 (ref_28) 2018; 15 Thakral (ref_38) 2012; 13 Yamasaki (ref_44) 2017; 494 Xia (ref_23) 2017; 534 Bujard (ref_20) 2017; 97 Li (ref_13) 2018; 279 Doreth (ref_25) 2018; 122 Kaminska (ref_7) 2014; 31 Surwase (ref_27) 2013; 10 Kojo (ref_30) 2018; 545 Hancock (ref_31) 2000; 17 |
| References_xml | – volume: 81 start-page: 159 year: 2012 ident: ref_14 article-title: Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2012.02.004 – volume: 2015 start-page: 1 year: 2015 ident: ref_33 article-title: Impact of Solubilizing Additives on Supersaturation.and Membrane Transport of Drugs publication-title: Pharm. Res. – volume: 534 start-page: 272 year: 2017 ident: ref_23 article-title: Different effects of silica added internal or external on in vitro dissolution of indomethacin hot-melt extrudates publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2017.10.041 – ident: ref_22 doi: 10.3390/biom9070281 – volume: 18 start-page: 599 year: 1992 ident: ref_37 article-title: Hansen solubility parameters for selected cellulose ether derivatives and their use in the pharmaceutical industry publication-title: Drug Dev. Ind. Pharm. doi: 10.3109/03639049209043713 – ident: ref_24 doi: 10.3390/pharmaceutics11070328 – volume: 42 start-page: 28 year: 2016 ident: ref_29 article-title: Sugars as solid dispersion carrier to improve solubility and dissolution of the BCS class II drug: Clotrimazole publication-title: Drug Dev. Ind. Pharm. doi: 10.3109/03639045.2015.1024683 – volume: 567 start-page: 118415 year: 2019 ident: ref_21 article-title: Risk assessment and QbD based optimization of an Eprosartan mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2019.06.006 – volume: 17 start-page: 397 year: 2000 ident: ref_31 article-title: What is the True Solubility Advantage for Amorphous Pharmaceuticals? publication-title: Pharm. Res. doi: 10.1023/A:1007516718048 – volume: 96 start-page: 2686 year: 2007 ident: ref_3 article-title: Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations publication-title: J. Pharm. Sci. doi: 10.1002/jps.20906 – volume: 137 start-page: 148 year: 2019 ident: ref_1 article-title: Effect of preparation method on the surface properties and UV imaging of indomethacin solid dispersions publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2019.03.002 – volume: 12 start-page: 496 year: 2015 ident: ref_15 article-title: Glass-liquid phase separation in highly supersaturated aqueous solutions of telaprevir publication-title: Mol. Pharm. doi: 10.1021/mp500573z – volume: 279 start-page: 114 year: 2018 ident: ref_13 article-title: Tailoring supersaturation from amorphous solid dispersions publication-title: J. Control. Release doi: 10.1016/j.jconrel.2018.04.014 – volume: 122 start-page: 62 year: 2018 ident: ref_25 article-title: Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2017.10.001 – volume: 133 start-page: 122 year: 2018 ident: ref_6 article-title: Early stages of drug crystallization from amorphous solid dispersion via fractal analysis based on chemical imaging publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2018.10.007 – volume: 11 start-page: 774 year: 2018 ident: ref_43 article-title: iNOS- and NOX1-dependent ROS production maintains bacterial homeostasis in the ileum of mice publication-title: Mucosal Immunol. doi: 10.1038/mi.2017.106 – volume: 15 start-page: 3489 year: 2018 ident: ref_9 article-title: Supersaturation Potential of Ordered Mesoporous Silica Delivery Systems. Part 1: Dissolution Performance and Drug Membrane Transport Rates publication-title: Mol. Pharm. doi: 10.1021/acs.molpharmaceut.8b00488 – volume: 554 start-page: 190 year: 2019 ident: ref_18 article-title: Selection of the suitable polymer for supercritical fluid assisted preparation of carvedilol solid dispersions publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2018.11.015 – volume: 10 start-page: 065012 year: 2015 ident: ref_17 article-title: Study on size effect of the silica nanospheres with solid core and mesoporous shell on cellular uptake publication-title: Biomed. Mater. doi: 10.1088/1748-6041/10/6/065012 – volume: 8 start-page: 17166 year: 2016 ident: ref_11 article-title: Charge-Reversal APTES-Modified Mesoporous Silica Nanoparticles with High Drug Loading and Release Controllability publication-title: ACS Appl. Mater. Interfaces doi: 10.1021/acsami.6b05370 – volume: 545 start-page: 19 year: 2018 ident: ref_30 article-title: Enhanced biopharmaceutical effects of tranilast on experimental colitis model with use of self-micellizing solid dispersion technology publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2018.04.053 – volume: 31 start-page: 5722 year: 2015 ident: ref_32 article-title: Biocompatible colloidal dispersions as potential formulations of natural pyrethrins: A structural and efficacy study publication-title: Langmuir doi: 10.1021/acs.langmuir.5b00246 – volume: 7 start-page: 225 year: 2019 ident: ref_16 article-title: Encapsulation and Controlled Release of Resveratrol Within Functionalized Mesoporous Silica Nanoparticles for Prostate Cancer Therapy publication-title: Front. Bioeng. Biotechnol. doi: 10.3389/fbioe.2019.00225 – volume: 20 start-page: 204 year: 2019 ident: ref_35 article-title: Effect of Tetrabutylammonium Bromide-Based Deep Eutectic Solvents on the Aqueous Solubility of Indomethacin at Various Temperatures: Measurement, Modeling, and Prediction with Three-Dimensional Hansen Solubility Parameters publication-title: AAPS PharmSciTech doi: 10.1208/s12249-019-1373-4 – volume: 51 start-page: 308 year: 2019 ident: ref_2 article-title: Molecular landmarks of tumor hypoxia across cancer types publication-title: Nat. Genet. doi: 10.1038/s41588-018-0318-2 – volume: 97 start-page: 143 year: 2017 ident: ref_20 article-title: HDM-PAMPA to predict gastrointestinal absorption, binding percentage, equilibrium and kinetics constants with human serum albumin and using 2 end-point measurements publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2016.11.001 – volume: 75 start-page: 354 year: 2010 ident: ref_5 article-title: Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2010.04.009 – volume: 129 start-page: 1 year: 2019 ident: ref_42 article-title: Molecular structure and impact of amorphization strategies on intrinsic dissolution of spray dried indomethacin publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2018.12.010 – volume: 31 start-page: 2887 year: 2014 ident: ref_7 article-title: Enhancement of the physical stability of amorphous indomethacin by mixing it with octaacetylmaltose. inter and intra molecular studies publication-title: Pharm. Res. doi: 10.1007/s11095-014-1385-4 – volume: 13 start-page: 59 year: 2012 ident: ref_38 article-title: Soluplus-solubilized citrated camptothecin--a potential drug delivery strategy in colon cancer publication-title: AAPS PharmSciTech doi: 10.1208/s12249-011-9720-0 – volume: 15 start-page: 1037 year: 2018 ident: ref_28 article-title: Polymorphism of Indomethacin in Semicrystalline Dispersions: Formation, Transformation, and Segregation publication-title: Mol. Pharm. doi: 10.1021/acs.molpharmaceut.7b00930 – volume: 512 start-page: 118 year: 2016 ident: ref_4 article-title: Enhanced oral delivery of celecoxib via the development of a supersaturable amorphous formulation utilising mesoporous silica and co-loaded HPMCAS publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2016.08.034 – volume: 561 start-page: 324 year: 2019 ident: ref_41 article-title: Influence of mechanical and thermal energy on nifedipine amorphous solid dispersions prepared by hot melt extrusion: Preparation and physical stability publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2019.03.014 – volume: 25 start-page: 198 year: 2018 ident: ref_19 article-title: Preparation of curcumin self-micelle solid dispersion with enhanced bioavailability and cytotoxic activity by mechanochemistry publication-title: Drug Deliv. doi: 10.1080/10717544.2017.1422298 – volume: 103 start-page: 2829 year: 2014 ident: ref_40 article-title: Anti-plasticizing Effect of Amorphous Indomethacin Induced by Specific Intermolecular Interactions with PVA Copolymer publication-title: J. Pharm. Sci. doi: 10.1002/jps.24023 – volume: 10 start-page: 8796 year: 2018 ident: ref_12 article-title: Combining autophagy-inducing peptides and brefeldin A delivered by perinuclear-localized mesoporous silica nanoparticles: A manipulation strategy for ER-phagy publication-title: Nanoscale doi: 10.1039/C8NR00872H – volume: 10 start-page: 4472 year: 2013 ident: ref_27 article-title: Indomethacin: New polymorphs of an old drug publication-title: Mol. Pharm. doi: 10.1021/mp400299a – volume: 43 start-page: 42 year: 2016 ident: ref_34 article-title: Solubility and dissolution performances of spray dried solid dispersion of Efavirenz in Soluplus publication-title: Drug Dev. Ind. Pharm. doi: 10.1080/03639045.2016.1205598 – volume: 494 start-page: 188 year: 2017 ident: ref_44 article-title: Fluorescence-labeled liposome accumulation in injured colon of a mouse model of T-cell transfer-mediated inflammatory bowel disease publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2017.10.058 – volume: 139 start-page: 132 year: 2019 ident: ref_8 article-title: Exploring the use of spray congealing to produce solid dispersions with enhanced indomethacin bioavailability: In vitro characterization and in vivo study publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2019.03.020 – volume: 136 start-page: 45 year: 2009 ident: ref_26 article-title: Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation publication-title: J. Control Release doi: 10.1016/j.jconrel.2009.01.027 – volume: 94 start-page: 106 year: 2015 ident: ref_36 article-title: Physicochemical properties of tadalafil solid dispersions—Impact of polymer on the apparent solubility and dissolution rate of tadalafil publication-title: Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2015.04.031 – ident: ref_10 doi: 10.3390/pharmaceutics11060269 – volume: 36 start-page: 105 year: 2019 ident: ref_39 article-title: A Single Hydrogen to Fluorine Substitution Reverses the Trend of Surface Composition Enrichment of Sorafenib Amorphous Solid Dispersion upon Moisture Exposure publication-title: Pharm. Res. doi: 10.1007/s11095-019-2632-5 |
| SSID | ssj0000331839 |
| Score | 2.2586095 |
| Snippet | This work explored absorption efficacy via an in vivo imaging system and parallel artificial membrane penetration in indomethacin (IMC) solid dispersion (SD)... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 144 |
| SubjectTerms | bioavailability indomethacin mesoporous silica nanoparticles solid dispersion solubility |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp15K33VfTKHkFDe2JVtyb22TkBZSFpK0uRnr1RiMFby7hf0x_a-dsfdZArn0aMt6oBl5vhlJ3zD2vvQiS0pTx6lyPBY-EbHyeRLrWjgplEYLRHeHz74Xp5fi21V-tZXqi86EjfTA48QdJiavEXNkAv1tkXilC68szy06V1jiB2iENm_LmRr-wZx0tRyv7HD06w9vrjch4mmKLj-5EjvGaODsvw1o_ntecssAnTxkD5bIET6NI37E7rnuMdufjB0uDuBic5NqegD7MNmQUi-esD_Ha1pvCB4Q9sF5aBsLRw1xhVPMDEb2clhRFDoLdPkEztw0IEoP8ymcNxTjg7qzMAntgmLegKh3aG4SQt8u4CeC157anuvWwVE__wVfOxsoU3Vtmu4jPsGPZtaHoZXh4Xd4yi5Pji--nMbL1AyxEVLOYimMzlWh0bpLi05QhuJ2Bm0dN7wuvLQ5Qhmj0wLnzMqS9vu4NKX1zqi8Vgl_xva60LkXDAigZV6nWKhE6YtSe5Sds85kVnCrIyZWMqrMkrec0me0FfovJNrqVtFG7MO62s1I3HFXhc-kAOuPiXd7eIHaWC21sbpLGyP2bqU-Fa5T2nypO4cCqjJOWZ6JnTFiz0d1WnfFs4R4HpOIyR1F2xnLbknXXA9c4JJmVuUv_8fgX7H7NBd0Jj1NXrO9WT93bxByzfTbYXX9Be8oL9k priority: 102 providerName: Directory of Open Access Journals |
| Title | Evaluation of the Solid Dispersion System Engineered from Mesoporous Silica and Polymers for the Poorly Water Soluble Drug Indomethacin: In Vitro and In Vivo |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32050600 https://www.proquest.com/docview/2354739262 https://pubmed.ncbi.nlm.nih.gov/PMC7076385 https://doaj.org/article/0c5a6562476140f8b6f8d35d713c5afa |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfG9sIL4pvwURkJ7WkZSezECRJCjHUaSJ0qtsLeovhrixTFI20R_WP4X7lL0paiIsRbHMdO4jvnfneOf0fIq8zyKMhU4YepYT63AfdTGwe-LLgRPJVggXDv8OgsOZ3wT5fx5Q5ZEir0Azjd6tphPqlJUx3--LZ4BxP-LXqc4LK_vrleR3-nIXjz6CXcIntgnAQmNRj1iL_9ODNU4qxda84wv1rEun09f-9pw2K1xP7b0OifP1X-ZqVO7pI7Pbyk7zt9uEd2TH2f7I-7Gy4O6MV6u9X0gO7T8Zq5evGA_ByuuL-psxSwIT13VanpcYmE4hhYox3FOV3yGBpNcYcKHZmpg1F08yk9LzEQSIta07GrFhgYpwCN2-7GzjXVgn4FhNtg33NZGXrczK_ox1o7TGddqLJ-AyX6pZw1ru2lLXx3D8nkZHjx4dTv8zf4igsx8wVXMk4TCRBAaPCUItAJo8AgMsWKxAodA95RMkxgzLTIcFGQCZVpa1QaF2nAHpHd2tXmCaGI4iIrQ6hMeWaTTFqQo9FGRZozLT3ClzLKVU9ujjk2qhycHBRtvlW0HjlcNbvp2D3-1eAIFWB1MZJztydcc5X3cz0PVFwATI64AOwT2FQmNtUs1iJkUGMLj7xcqk8OkxlXaIragIDyiGEqaKRw9MjjTp1Wt2JRgGSQgUfEhqJtPMtmTV1et4ThAkc2jZ_-79s-I7fxCH9SD4PnZHfWzM0LwGAzOSB7R8Oz8edBG8MYtHPsF7JAOOA |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+the+Solid+Dispersion+System+Engineered+from+Mesoporous+Silica+and+Polymers+for+the+Poorly+Water+Soluble+Drug+Indomethacin%3A+In+Vitro+and+In+Vivo&rft.jtitle=Pharmaceutics&rft.au=Xi%2C+Ziyue&rft.au=Zhang%2C+Wei&rft.au=Fei%2C+Yali&rft.au=Cui%2C+Mingshu&rft.date=2020-02-10&rft.issn=1999-4923&rft.eissn=1999-4923&rft.volume=12&rft.issue=2&rft.spage=144&rft_id=info:doi/10.3390%2Fpharmaceutics12020144&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_pharmaceutics12020144 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4923&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4923&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4923&client=summon |